Buy sildenafil citrate without medical prescription from a licensed pharmacy and save up to 77%. Best Price: $0.27 per pill, SALES! WHAT ARE THE KEY STATISTICS ABOUT PROSTATE CANCER? Prostate cancer is the most common cancer, excluding nonmelanoma skin cancers, in American men. The American Cancer Society estimates during 2000 approximately 180,400 new cases of prostate cancer will be diagnosed in the United States.
Prostate cancer is the second leading cause of cancer death in men, exceeded only by lung cancer. The American Cancer Society estimates that 31,900 men in the United States will die of this disease during 2000. Prostate cancer accounts for about 11% of male cancer-related deaths.
The 5-year survival rates discussed in this section refer to the percent of men who live at least 5 years after their cancer is diagnosed. It is important to remember that many of these men live much longer than 5 years after diagnosis. Of course, 5-year survival rates are based on patients diagnosed and initially treated more than 5 years ago. Improvements in treatment often result in a more favorable outlook for recently diagnosed men. And the survival statistics in this section include all men diagnosed with prostate cancer, regardless of their treatment. The prognosis for a man depends on the extent of his cancer but is also affected by factors such as the treatment he chooses and other individual aspects of his medical situation.
Eighty-nine percent of men diagnosed with prostate cancer survive at least 5 years, and 63% survive at least 10 years. Fifty-eight percent of all prostate cancers are found while they are still localized (that is, confined to the prostate), and the 5-year relative survival rate for men with localized prostate cancer is 100%. Thirty-one percent of prostate cancers have already spread locally (to tissues near the prostate) at the time of diagnosis. The 5-year survival rate for these men is 94%. Among the 11% of men whose prostate cancers have already spread to distant parts of the body at the time of diagnosis, about 31% are expected to survive at least five years.